Cite
HARVARD Citation
Coleman, R. et al. (n.d.). O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. International journal of gynecological cancer. pp. A3-A4. [Online].